Safety and Efficacy of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects

Trial Profile

Safety and Efficacy of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Saroglitazar (Primary)
  • Indications Dyslipidaemias; Hypertriglyceridaemia; Lipodystrophy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 26 Feb 2018 Results of development of a three-point linear regression model and prediction of human exposure by using data from this study published in the Clinical Therapeutics.
    • 30 Oct 2017 New trial record
    • 11 Oct 2017 Results published in the Clinical Drug Investigation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top